A Aralex Aachen research explorer

Search

From

To

Institution

Field

Type

Open access only Cited by patents (Lens) Include non-Aachen papers (citing/cited)

Papers matching “IKZF1 deletion” 4

Sort: Relevance Cited Newest Oldest Fwci Patents ⇩ CSV

Not finding it? Sign in to also search OpenAlex live.

Improved Outcome for ALL by Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for Other Risk Groups
2023 Journal of Clinical Oncology article Medicine Acute Lymphoblastic Leukemia research Open access

Rob Pieters, Hester de Groot‐Kruseman, Marta F. Fiocco, Femke Verwer, Merian van Overveld, Edwin Sonneveld, +11 more

42

citations
Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study
2021 The Lancet Haematology article Medicine Acute Lymphoblastic Leukemia research Open access

Naomi Michels, Judith M. Boer, Amir Enshaei, Rosemary Sutton, Mats Marshall Heyman, Sabine Ebert, +14 more

19

citations
Tyrosine kinase inhibitor resistance in de novo BCR::ABL1–positive BCP-ALL beyond kinase domain mutations
2024 Blood Advances article Medicine Chronic Myeloid Leukemia Treatments Open access

Inge van Outersterp, Judith M. Boer, Cesca van de Ven, Caitlin E. J. Reichert, Aurélie Boeree, Brian Kruisinga, +5 more

10

citations
Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study
2020 The Lancet Haematology article Medicine Acute Lymphoblastic Leukemia research Open access

Monique L. den Boer, Gunnar Cario, Anthony V. Moorman, Judith M. Boer, Hester A. de Groot‐Kruseman, Marta F. Fiocco, +18 more

71

citations

4 results